The purpose of the study is to compare disease-free survival (DFS) of women treated with
concomitant trastuzumab plus docetaxel followed by FEC to that of the women treated with the
same regimen followed by single-agent trastuzumab to complete one year of trastuzumab
administration as adjuvant treatments of early HER2-positive breast cancer.